Baseline characteristics of the participants
| Characteristic . | Discovery cohort (n = 64) . | Validation cohort (n = 20) . | |||
|---|---|---|---|---|---|
| HC (n = 26) . | CP (n = 15) . | ARTC (n = 23) . | HC (n = 10) . | ARTC/CP (n = 10) . | |
| Sex, n (%) | |||||
| Male | 25 (96%) | 12 (80%) | 21 (91%) | 6 (60%) | 8 (80%) |
| Female | 1 (4%) | 3 (20%) | 2 (9%) | 4 (40%) | 2 (20%) |
| Age, y | |||||
| Median | 46 | 44 | 47 | 48 | 47 |
| Q1-Q3 | 39-54 | 37-48 | 43-52 | 45-64 | 45-59 |
| CD4+ T cells/mm3 | |||||
| Median | 761 | 477 | 463 | 745 | 371 |
| Q1-Q3 | 588-904 | 247-591 | 322-684 | 521-994 | 305-589 |
| HIV-1 log10 copies/mm3 | |||||
| Median | 1.8 | 4.2 | 1.7 | 1.9 | 1.9 |
| Q1-Q3 | 1.7-2.4 | 3.6-4.6 | 1.7-2.1 | 1.7-3.0 | 1.7-4.7 |
| Protective HLA alleles, n (%)* | |||||
| Any | 16 (62%) | 7 (47%) | 14 (61%) | 7 (70%) | 4 (40%) |
| B*5701/03 | 10 (38%) | 4 (27%) | 7 (30%) | 7 (70%) | 2 (20%) |
| B*2705 | 5 (19%) | 2 (13%) | 6 (26%) | 0 (0%) | 1 (10%) |
| B*5801 | 2 (8%) | 1 (7%) | 1 (4%) | 0 (0%) | 1 (10%) |
| Characteristic . | Discovery cohort (n = 64) . | Validation cohort (n = 20) . | |||
|---|---|---|---|---|---|
| HC (n = 26) . | CP (n = 15) . | ARTC (n = 23) . | HC (n = 10) . | ARTC/CP (n = 10) . | |
| Sex, n (%) | |||||
| Male | 25 (96%) | 12 (80%) | 21 (91%) | 6 (60%) | 8 (80%) |
| Female | 1 (4%) | 3 (20%) | 2 (9%) | 4 (40%) | 2 (20%) |
| Age, y | |||||
| Median | 46 | 44 | 47 | 48 | 47 |
| Q1-Q3 | 39-54 | 37-48 | 43-52 | 45-64 | 45-59 |
| CD4+ T cells/mm3 | |||||
| Median | 761 | 477 | 463 | 745 | 371 |
| Q1-Q3 | 588-904 | 247-591 | 322-684 | 521-994 | 305-589 |
| HIV-1 log10 copies/mm3 | |||||
| Median | 1.8 | 4.2 | 1.7 | 1.9 | 1.9 |
| Q1-Q3 | 1.7-2.4 | 3.6-4.6 | 1.7-2.1 | 1.7-3.0 | 1.7-4.7 |
| Protective HLA alleles, n (%)* | |||||
| Any | 16 (62%) | 7 (47%) | 14 (61%) | 7 (70%) | 4 (40%) |
| B*5701/03 | 10 (38%) | 4 (27%) | 7 (30%) | 7 (70%) | 2 (20%) |
| B*2705 | 5 (19%) | 2 (13%) | 6 (26%) | 0 (0%) | 1 (10%) |
| B*5801 | 2 (8%) | 1 (7%) | 1 (4%) | 0 (0%) | 1 (10%) |
HC indicates HIV-1 controllers; CP, chronic progressors; and ARTC, ART-treated subjects.
Protective alleles are defined here as B*5701, B*5703, B*2705, and B*5801.